MedTrace Logo

Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.

NCT07622004 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2026-06-03

No results posted yet for this study

Summary

To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.

Conditions

  • Glabellar Lines

Interventions

DRUG

Botulinum Toxin Type A Injection [INI101]

Single administration, Day 0, 20 units

DRUG

Botulinum Toxin Type A Injection [Botox]

Single administration, Day 0, 20 units

Sponsors & Collaborators

  • INIBIO Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-27
Primary Completion
2022-01-30
Completion
2022-03-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07622004 on ClinicalTrials.gov